الصفحة الرئيسية>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>ASLAN003

ASLAN003 (Synonyms: ASLAN003)

رقم الكتالوجGC38463

ASLAN003 (ASLAN003) هو مثبط فعال عن طريق الفم وفعال لنزع هيدروجين ثنائي هيدروجين (DHODH) مع IC50 من 35 نانومتر لإنزيم DHODH البشري. ASLAN003 يثبط تخليق البروتين عن طريق تنشيط عوامل النسخ AP-1. ASLAN003 يحث على موت الخلايا المبرمج ويطيل بشكل كبير البقاء على قيد الحياة في الفئران xenograft ابيضاض الدم النخاعي الحاد (AML).

Products are for research use only. Not for human use. We do not sell to patients.

ASLAN003 التركيب الكيميائي

Cas No.: 1035688-66-4

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
39٫00
متوفر
1mg
17٫00
متوفر
5mg
50٫00
متوفر
10mg
81٫00
متوفر
25mg
171٫00
متوفر
50mg
279٫00
متوفر
100mg
450٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ASLAN003 is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) which has the potential to be a first-in-class candidate in AML (Acute Myelogenous Leukemia). ASLAN003 has antitumor activity[1].

[1]. Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure and Function TÄllberg, 14-17 June 2019

مراجعات

Review for ASLAN003

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ASLAN003

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.